Product Description
Cibenzoline is a class I antiarrhythmic drug with limited class III and IV activity which can be administered orally or intravenously. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1379150/)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Egypt | France | Portugal
Approved Indications: None
Known Adverse Events: None
Company: TOA EIYO
Company Location: Asia Pacific
Company Founding Year: 1941
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cardiomyopathy, Hypertrophic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2080224827 |
jRCT2080224827 | P2 |
Completed |
Cardiomyopathy, Hypertrophic |
2023-08-31 |
|||
JapicCTI-194910 |
JapicCTI-194910 | P2 |
Active |
Cardiomyopathy, Hypertrophic |
2021-08-31 |